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Abstract
Many antimicrobial and anti-tumour drugs elicit hormetic responses characterised by low-
dose stimulation and high-dose inhibition. While this can have profound consequences for
human health, with low drug concentrations actually stimulating pathogen or tumour growth,
the mechanistic understanding behind such responses is still lacking. We propose a novel,
simple but general mechanism that could give rise to hormesis in systems where an inhibitor
acts on an enzyme. At its core is one of the basic building blocks in intracellular signalling,
the dual phosphorylation-dephosphorylation motif, found in diverse regulatory processes
including control of cell proliferation and programmed cell death. Our analytically-derived
conditions for observing hormesis provide clues as to why this mechanism has not been pre-
viously identified. Current mathematical models regularly make simplifying assumptions
that lack empirical support but inadvertently preclude the observation of hormesis. In addi-
tion, due to the inherent population heterogeneities, the presence of hormesis is likely to be
masked in empirical population-level studies. Therefore, examining hormetic responses at
single-cell level coupled with improved mathematical models could substantially enhance
detection and mechanistic understanding of hormesis.
Author Summary
Hormesis is a highly controversial and poorly understood phenomenon. It describes the
idea that an inhibitor molecule, like an anti-cancer or anti-microbial drug, can inadver-
tently stimulate cell growth instead of suppressing it. This can have a profound effect on
human health leading to failures in clinical treatments. Therefore, getting at the mechanis-
tic basis of hormesis is critical for drug development and clinical practice, however molec-
ular mechanisms underpinning hormesis remain poorly understood. In this paper we use
a mathematical model to propose a simple and yet general mechanism that could explain
why we find hormesis so widely in living systems. In particular, we discover that hormesis
is present within a fundamental structure that forms a basic building block of many intra-
cellular signalling pathways found in diverse processes including control of cell reproduc-
tion and programmed cell death. The benefits of our study are two-fold. Having simple
molecular understanding of the causes of hormetic responses can greatly improve the
design of new drug compounds that avoid such responses. Moreover, due to the
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fundamental nature of the newly proposed mechanism, our findings have a potential
broad applicability to both anti-cancer and anti-microbial drugs.
Introduction
Hormesis is a phenomenon describing biphasic dose response relationships that exhibit low-
dose stimulation and high-dose inhibition [1]. Many medical agents such as antibacterials,
antifungals, and anti-tumour drugs have been found to display hormetic response [2] with the
earliest observations dating back to 1800s. In particular, low concentrations of certain antifun-
gals were found to stimulate fungal growth [3] or metabolism [4] while inducing toxicity at
high concentrations. From the early 1920s the concept of low-dose stimulation and high-dose
toxicity of various chemical elements with respect to bacterial growth was widely recognised
[5]. We now know that bacteria can exhibit hormetic response to a wide range of antibiotic
drugs, regardless of their mode of action [6]. This phenomenon is also found in tumour cells
exposed to anti-tumour drugs. In fact, hormesis has been observed in an astonishingly broad
range of tumour types including pancreatic, colon and breast (reviewed in [7]).
Despite the overwhelming body of research, some dating back a century, that documents
hormetic responses to a broad range of compounds, their clinical significance has only rela-
tively recently come to the fore [2]. The consequence of hormesis could have a profound effect
for human health [8, 9]. Drug concentration generally varies substantially within the human
body and as drug gets cleared, the associated low concentration can in turn stimulate pathogen
or tumour growth. Therefore understanding the mechanistic basis of hormesis is vital for both
drug development and clinical practice.
The vast majority of targets for antibiotics, antifungals and anti-tumour drugs fall into the
following categories: enzymes, receptors, transporters and DNA/RNA and the ribosome [10].
However how such drug-target interactions lead to hormesis remains poorly understood. The
biological explanations put forward are overcompensation after a disruption of homeostasis
(reviewed in [11]), direct stimulatory response [12], superimposition of different monotonic
dose-response curves [13], or heterogenic susceptibility of different tissues to the same stimuli
[14]. These explanations provide understanding of hormesis at a phenotypic level but lack
understanding at the molecular level. Some inroads have also been made with respect to mam-
malian cells focusing on drug mechanisms mediated via receptor and/or cell signalling path-
ways (reviewed in [7]). For example, biphasic dose response could occur through interaction
of two different receptor subtypes that mediate/activate opposing stimulatory and inhibitory
pathways via the same antagonist [15]. However, hormetic response is a built in feature of
such receptor mediated mechanisms rather than an emergent property of the underlying bio-
logical system.
An area of research where understanding of the mechanisms giving rise to hormesis is par-
ticularly lacking involves enzyme-targeting drugs. Known as enzyme inhibitors, they are
designed to block enzyme activity leading to disruption of bacterial cell wall [16], fungal mem-
branes [17] and fungal cell wall [18] as well as programmed tumour cell death [19], to name a
few. With regards to hormetic dose-responses to antibiotics, a recent study focusing on inhibi-
tion of a specific enzyme, Dihydropteroate synthase, suggested the involvement of bacterial
quorum sensing [20]. To our knowledge, mechanisms behind hormetic dose-response to
enzyme-inhibiting antifungals are not known.
In recent years kinase inhibitors, a subset of enzyme inhibitors, have been shown to be very
effective therapeutic agents in a broad range of diseases, including cancers. Amongst other
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enzyme inhibitors, significant attention has been focused on those inhibiting the mitogen-
activated protein kinase (MAPK) pathway [21–24], which is of fundamental importance to
human health as abnormal regulations of MAPK contribute to tumour progression [25].
The observations of hormesis in MAPKs as a result of inhibition of BRAF oncogene are
widespread: low doses of RAF inhibitors designed to cease tumour proliferation [26] can cause
a paradoxical activation of tumour cell activity through undesired MAPK up-regulation [8, 9,
27–32]. Current explanations of hormetic responses induced by RAF kinase inhibition involve
complex phenomena affecting regulatory mechanisms, feedback pathways or enzymatic activ-
ity [33], making them difficult to generalise. More generally, enzyme competition for the same
substrate was recently proposed as a simpler mechanism giving rise to hormetic effects of
enzyme-targeting Alzheimer’s drugs [34].
In this paper we put forward a novel, simple but general mechanism driving hormetic
responses in systems where an inhibitor acts on an enzyme. We develop a mathematical model
based on a basic building block in intracellular signalling, namely a dual phosphorylation-
dephosphorylation motif, to which a kinase inhibitor is applied. In a broader context, dual-
phosphorylation can be found in diverse processes such as circadian rhythms [35], virulence
regulation [36, 37], mitotic entry [38], transcription [39, 40], cytokine production [40], as well
as in MAPK pathways which regulate primary cellular activities in eukaryotes including prolif-
eration and programmed cell death [41, 42].
The model demonstrates that under certain conditions the steady state amount of the dou-
ble-phosphorylated protein substrate in the cycle can substantially increase at low inhibitor
doses compared to the base level without inhibition. Therefore the dose-response curve of the
double-phosphorylated substrate possesses a hallmark of hormesis: it is upward sloping at low
inhibitor doses and downward sloping at high inhibitor doses. The existence of hormesis in
our model depends on the mechanism of inhibition and the dissociation rates of the kinase-
substrate-inhibitor complexes. We also found that the magnitude of hormetic responses
depends on the substrate-kinase ratio in a non-monotone way.
The benefits of our study are two-fold. Our mechanism is based on a principal component
of intracellular signalling pathways, and as such has a potential broad applicability. Moreover
having simple molecular understanding of the causes of hormetic responses can greatly
improve the design of new drug compounds that avoid such responses.
Materials and Methods
The mathematical model
We consider a simple dual phosphorylation-dephosphorylation motif, whereby a distinct
kinase protein is phosphorylating a separate protein substrate. Multiple phosphorylations can
occur in close proximity or in diverse sites on a protein and here we focus on the former,
instances of which can be found in activation of conventional MAPK enzymes [43], cell-cycle
regulation via cyclin-dependent kinase 1 [44], regulation of other non-MAPK kinases [45] and
ion channel trafficking [46]. The motif we consider is a subset of futile cycles [47, 48] also
known as a single stage module in the context of MAPK pathways [49, 50]. Based on the exper-
imental evidence for MAPK pathways [51–53] we assume that our motif follows a distributive
mechanism consisting of two sequential phosphorylation steps and two sequential dephos-
phorylation steps that share the same intermediate mono-phosphorylated form. In particular,
the protein substrate (C) is first converted into a mono-phosphorylated form (CP) and subse-
quently into a double-phosphorylated form (CPP), through a chain of reactions facilitated by a
kinase (kin). Conversely CPP is converted back to CP which is subsequently converted to C,
through a chain of reactions facilitated by a phosphatase (pho). In the distributive mechanism,
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the kinase(phosphatase) facilitates at most one phosphorylation (dephosphorylation) in each
molecular encounter [48].
Therefore our dual phosphorylation-dephosphorylation motif can be described by the fol-
lowing reaction kinetic equations, which are a simplification of the reaction scheme described
in [54]:
Cá kin Ñk1
k 1
C   kin!k2 CP á kin;
CP á kin Ñ
k3
k 3
CP   kin!k4 CPP á kin;
CPP á pho Ñ
k5
k 5
CPP   pho!k6 CP á pho;
CP á pho Ñ
k7
k 7
CP   pho!k8 Cá pho:
Ö1Ü
Next we describe the assumptions behind the introduction of an inhibitor into Eq (1), based
on the general modifier mechanism also known as hyperbolic or partial competitive inhibition
[55]. We assume that the inhibitor (inh) is able to react with the kinase and the substrate-
kinase intermediate complexes C   kin and CP   kin according to the following inhibition
scheme:
kiná inh Ñ
df
dr
kin   inh;
C   kiná inh Ñe1
e 1
C   kin   inh Ñe2
e 2
Cá kin   inh;
CP   kiná inh Ñ
e3
e 3
CP   kin   inh Ñ
e4
e 4
CP á kin   inh:
Ö2Ü
The first- and second-order rates ki and ei in Eqs (1) and (2) and the association and dissocia-
tion rates df and dr in Eq (2) are considered dimensionless. In our system intermediate sub-
strate-kinase-inhibitor complexes are able to dissociate into a substrate and kinase-inhibitor
complex with forward e2, e4 and backward e−2, e−4 rates [56].
The model describing the time evolution of the substrate, kinase, phosphatase and inhibitor
concentrations is based on the law of mass action and assumes the total conservation of mass
holds for all four compounds. The details of the system of 9 differential equations and the cor-
responding analysis are presented in S1 Appendix. (with Supplementary Tables A1 and A2
containing model parameter values). This model system is studied under steady state condi-
tions, that is, when all concentrations of reactants have reached a dynamic equilibrium.
Numerical simulations are conducted with Matcont, a continuation package in MATLAB
used for numerical bifurcation analysis of ODEs [57].
Results
In the absence of an inhibitor, the double phosphorylation motif Eq (1) can possess either a
single or two stable steady states of the doubly-phosphorylated form of the substrate CPP, [50,
54, 58, 59]. Therefore in our study we consider two cases: first, when the motif Eq (1) is mono-
stable and second, when this motif is bi-stable.
In the case of a single stable steady state (CPP⇤) in the absence of an inhibitor, we find that
CPP can exhibit biphasic (or hormetic) response to an inhibitor as illustrated in Fig 1. In partic-
ular, the observed dose-response curve in the presence of an inhibitor has an inverted U-
shape: for sufficiently low inhibitor doses the computed steady-state values of CPP increase
Kinase Inhibition and Hormesis
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monotonically, while for sufficiently large inhibitor doses, the computed steady-state values of
CPP monotonically decrease.
Moreover, by making simplifying assumptions that e−2 = e−4 = 0, e2>>e1, e4>>e3 and the
inhibitor has fast off rate, we can analytically derive the slope of the dose-response curve, in
other words the slope of the relationship between the steady-state value of CPP and the total
amount of inhibitor at low doses (see S1 Appendix for details). This allows us to identify two
primary factors necessary for the hormesis to be observed:
(C1) the strong dissociation effect of intermediate substrate-kinase-inhibitor complexes
C   kin   inh and CP   kin   inh, corresponding to e2, e4> 0,
(C2) large dissociation rate of kinase-inhibitor complexes.
Note that the hormesis is still observed in numerical simulations when e−2, e−4> 0 (Fig A1
in S1 Appendix).
In addition the above conditions (C1-C2) can also be used to forecast the presence of a hor-
metic dose response in the second case under our consideration, namely when in the absence
of an inhibitor the motif Eq (1) has two stable steady states CPP,1⇤ (Fig 2A) and CPP,2⇤ (Fig 2B).
In this case the numerical simulations predict that cells with high base level of double-phos-
phorylated substrate will respond differently to inhibition from the cells with low base level of
double-phosphorylated substrate. In particular, cells with initially high levels of CPP (at steady
state CPP,1⇤) will exhibit a monotone decreasing dose-response (Fig 2A) while cells with low
initial levels of CPP (at steady state CPP,2
⇤) will exhibit a hormetic response (Fig 2B).
The magnitude of hormetic response can differ between the mono- and bi-stable cases
under consideration as illustrated in Figs 1 and 2B. In the mono-stable case the CPP value at
dose inh⇤ is approximately two-fold higher compared to the base level CPP⇤ value in the
Fig 1. Dose response curve (log scale) for the double-phosphorylated substrate CPP in the presence
of an inhibitor (inhtot), in the case when the motif Eq (1) is monostable. In the absence of the inhibitor the
stable steady state value of the double-phosphorylated substrate is denoted by CPP*. With the inhibitor
present, the dose response exhibits hormetic properties whereby for sufficiently low inhibitor doses
(inhtotinh*) the computed steady state values of CPP increase monotonically, before monotonically
decreasing for inhibitor concentrations inhtot!inh*. The magnitude of hormetic response is calculated as a
difference between the CPP value at inh* and CPP*.
doi:10.1371/journal.pcbi.1005216.g001
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absence of an inhibitor (Fig 1). In the bi-stable case the CPP value at dose inh⇤ is approximately
six-fold higher than the base level CPP,2
⇤ value in the absence of an inhibitor (Fig 2B).
In general, we find that the ratio of total mass of protein substrate to kinase mass influences
the magnitude of hormetic response in a non-monotone way as shown in Fig 3. For sufficiently
small substrate-kinase ratio, a hormetic response is not observed (absence of hormesis is
labelled as 100% response in Fig 3 because the maximal response is equal to the baseline of no
inhibition). However, the hormetic response increases sharply as the substrate-kinase ratio
increases. Further increases of this ratio lead to a sharp decline in the magnitude of hormetic
response, which continues to increase slowly for sufficiently large substrate-kinase ratios (see
Fig 3 inset). Therefore, the magnitude of hormetic response peaks at intermediate values of the
substrate-kinase ratio, as frequently observed in the MAPK pathway [60] for example, while
hormesis is not observed for low substrate-kinase ratios.
Discussion
Hormetic responses to enzyme-targeting drugs have been observed in both prokaryotes [20,
61, 62] and eukaryotes [8, 9, 27, 31, 32] but the mechanistic understanding behind such
responses is still lacking. In this paper we focus on eukaryotic cells and propose a novel, simple
but general mechanism that could give rise to hormesis in systems where an inhibitor acts on
an enzyme.
At the core of our newly-proposed mechanism is one of the basic building blocks in intra-
cellular signalling, the dual phosphorylation-dephosphorylation motif, found in diverse regu-
latory processes including MAPK pathways which control cell proliferation and programmed
cell death in eukaryotes [41, 42]. We analytically derive conditions that lead to hormetic dose-
response of the doubly-phosphorylated substrate in the presence of a kinase inhibitor. The
conditions required for hormesis to be observed are surprisingly simple and involve two main
Fig 2. Dose response curve (log scale) for the double-phosphorylated substrate CPP in the presence of an inhibitor
(inhtot), in the case when the motif Eq (1) is bistable. In the absence of the inhibitor there are two stable steady states of the
double-phosphorylated substrate (A) CPP,1* and (B) CPP,2*. Cell populations at these two steady state will react differently to the
presence of an inhibitor: (A) cells at CPP,1* will exhibit a monotone dose-response while (B) cells at CPP,2* will exhibit a hormetic
dose response whereby for sufficiently low inhibitor doses (inhtotinh*) the computed steady state values of CPP increase
monotonically, before monotonically decreasing for inhibitor concentrations inhtot!inh*. The dotted lines indicate a discontinuous
jump in the steady state values of CPP in the presence of the inhibitor. The magnitude of hormetic response is calculated as a
difference between the CPP value at inh* and CPP,2*.
doi:10.1371/journal.pcbi.1005216.g002
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factors: (C1) strong dissociation effect of intermediate substrate-kinase-inhibitor complexes
and (C2) large dissociation rate of kinase-inhibitor complexes.
Crystallographic studies of kinase inhibitors bound to their targets demonstrate that a num-
ber of different conformational states can be induced. Type 1 kinase inhibitors are defined as
binding the kinase in its active conformation and crystal structures of ternary complexes of
ATP analogues bound with substrate peptides are reported (for review see [63, 64]). Indeed it
is not uncommon for crystal systems of substrate peptide complexes to be used in Structure
Based Design campaigns to develop Type 1 kinase inhibitors [65].
Given the fundamental nature of the dual phosphorylation-dephosphorylation motif and
the relative simplicity of the derived conditions necessary to observe hormesis, why was this
mechanism previously overlooked in theoretical literature? A further examination of the (C1)
condition could provide a potential answer. In general, when considering partial competitive
enzyme inhibition [55] as we do here, classical enzyme kinetics literature [55, 56] assumes not
only equilibrium concentrations of different enzyme species but it also assumes that at those
equilibrium concentrations there is no flux through substrate-kinase-inhibitor complexes.
However, we find that in our study as flux decreases the maximum hormetic response also
decreases (Fig 4) indicating that under the no-flux assumption, hormetic responses could be
overlooked.
Once a new mechanism is proposed to explain a particular biological phenomenon, ideally
it should be put to test. However, there are a number of difficulties associated with in vitro
tests of our model predictions. First, biochemical assays involved with in vitro studies are not
standardised and vary between research groups, making comparisons between already pub-
lished observations difficult. Second, testing our model predictions requires measurements of
single and double phosphorylation outputs, this could be problematic as antibody specificity
required to distinguish these outputs might not readily be available. This would particularly be
relevant for systems where phosphorylation sites are situated close together. Third, ensuring
that the condition for observing hormesis e2, e4> 0 is satisfied experimentally is challenging as
Fig 3. Maximum hormetic response. The maximum hormetic response is calculated as the maximal
increase in CPP over all inhibitor doses, relative to the base line amount of CPP in the absence of inhibition.
Since the baseline is represented at a level of 100%, hormesis is present if the maximum response strictly
exceeds the baseline (! 100%). This maximum response is plotted (black dots) as a function of different
substrate-kinase ratios achieved by varying the total mass of substrate and keeping the total mass of kinase
constant.
doi:10.1371/journal.pcbi.1005216.g003
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kinase biochemical assays would not usually include phosphatase activity. Furthermore vary-
ing rates of reactions individually or measuring fluxes in such systems is equally difficult.
Having discussed difficulties associated with testing our model in reductionist in vitro sys-
tems, we next consider whether these difficulties could be overcome with a cell-based experi-
mental systems. In particular, our model predicts that hormetic dose-response could be a
wide-spread feature of MAPK pathways when exposed to enzyme inhibitors. However we
argue here that the non-trivial biphasic dose-response associated with hormesis might often be
overlooked when performing experiments at cell population level, as we now discuss.
Consider the case where in the absence of an inhibitor, the double phosphorylation motif
Eq (1) possesses two stable steady states of the doubly-phosphorylated form of the substrate
CPP. This means that tumour cells within a population can be grouped into two types: type-1
cells with ‘high’ CPP and type-2 cells with ‘low’ CPP. In reality these heterogeneous cell pheno-
types can emerge not only due to multistability of the system [50, 54] but also due to stochastic
fluctuations which lead to different concentrations of the the total protein substrate [66, 67]. In
general, an untreated tumour is likely to harbour different proportions of cells in different phe-
notypic states [68].
We show that different cell types can respond differently to the presence of an inhibitor.
Namely, our model predicts that in certain cases cells with initially high levels of CPP (at steady
state CPP,1
⇤) will exhibit a monotone decreasing dose-response (Fig 2A) while cells with low
Fig 4. Relationship between the maximum hormetic response and the flux C   kin   inh! C + inh   kin.
The maximum hormetic response is calculated as the maximal increase in CPP over all inhibitor doses,
relative to the base line amount of CPP in the absence of inhibition. Since the baseline is represented at a level
of 100%, hormesis is present if the maximum response strictly exceeds the baseline (! 100%). The flux is
computed as e2[C   kin   inh] í eí2[C][kin   inh] using the steady state values [C](inh*), [kin   inh](inh*), [C   kin  
inh](inh*) with inh* being the dose with the maximum hormetic response (see Fig 1). As eí2 increases, the
flux decreases to 0.
doi:10.1371/journal.pcbi.1005216.g004
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initial levels of CPP (at steady state CPP,2
⇤) will exhibit a hormetic response (Fig 2B). This has
an important consequence for measuring CPP at a population level as it is frequently done
[69], as well as determining inhibitory concentrations (IC). Such consequences are best illus-
trated with the following example.
Let us assume, for example, that 88% of the tumour cells are type-1 cells and 12% of the
tumour cells are type-2 cells. We can then simulate our model to generate dose response curves
of CPP for both type-1 (Fig 5, green line) and type-2 (Fig 5, blue line) phenotypes. In addition,
we can also numerically generate sampled values of the combined dose response of the entire
population as would be measured, for instance, in a western blot or population-based imaging
assay for C PP (Fig 5, red dots). By fitting a logistic curve to the sampled values of the combined
dose response (Fig 5, red dashed line) we can estimate the inhibitor concentration causing
50% inhibition of the entire population, denoted IC50. However, the same inhibitor concentra-
tion has the opposing effects on the two sub-populations: while it inhibits type-1 cells, it actu-
ally stimulates type-2 cells. This can be observed by comparing steady-state values of CPP in
the absence of inhibition (CPP,1
⇤ for type-1 and CPP,2⇤ for type 2) to the steady-state values of
CPP in the presence of the inhibitor (CPP,1⇤⇤ for type-1 and CPP,2⇤⇤ for type 2) at the IC50 con-
centration estimated for the entire population (Fig 5). In particular, the inhibition of type-1
cells can be seen from CPP,1
⇤>CPP,1⇤⇤ while the stimulation of type-2 cells can be seen from
CPP,2⇤<CPP,2⇤⇤. Such unexpected stimulatory effects of the population-level IC50 exerted on
type-2 sub-population could be further amplified when taking into account the imperfect drug
penetration in a tumour [70]. In that case tumour cells would actually experience a lower
inhibitor concentration IC⇤<IC50, which could lead to significant increases in steady-state val-
ues of CPP (denoted by CPP,2
[ in Fig 5), compared to the steady-state values of CPP in the
absence of inhibition (denoted by CPP,2
⇤ in Fig 5). A numerical example with balanced type-1
and type-2 cell populations is presented in Fig A5 of S1 Appendix, showing that in this case it
is also possible to mask the hormetic response at the population level, although the maximal
hormetic response of the type-2 cells at the corresponding IC50 is substantially lower.
The presence of hormetic responses to an inhibitor which are masked at a population level
could, therefore, complicate the interpretation of, and understanding gained from, preclinical
models. Such complex sub-population effects have been noted for example in the NF-ĔB path-
way, controlling DNA transcription, cytokine production and cell survival [71]. In particular,
studies have shown that observing non-synchronous cells at a population level may under-rep-
resent oscillatory behaviour of nuclear shuttling [40, 72–74].
Examining hormetic responses at single-cell level could substantially improve detection
rates as well as help identify mechanisms driving hormesis. However, while measuring and
analysing single-cell bacterial dose response to antibiotics is already feasible [75], such meth-
odology has rarely been implemented for studying dose-responses of tumour cells. Therefore,
a wider application of single-cell dose-response techniques used for prokaryotes to tumour
cells will greatly enhance our understanding of hormesis in cancer settings.
The conclusions of our study are based on the assumption that the dual phosphorylation-
dephosphorylation motif presented in Eq (1) follows a distributive mechanism, whereby kinase
(phosphatase) facilitates at most one phosphorylation (dephosphorylation) in each molecular
encounter. This is motivated by the experimental evidence for MAPK pathways [51–53]. How-
ever, phosphorylation and dephosphorylation cycles can also follow a processive mechanism
in which the kinase (phosphatase) facilitates two or more phosphorylations (dephosphoryla-
tions) before the final product is released [48]. In addition, a quasi-processive mechanism has
been recently proposed to operate under the physiological condition of molecular crowding,
which is a critical factor converting distributive into processive phosphorylation [76–78]. Our
model can readily be extended to consider these alternative scenarios.
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The findings presented here are relevant to applications in drug discovery relating to
MAPK inhibition. Whereas inhibitors are specifically designed to target and suppress various
stages in the MAPK pathways, the hormesis phenomenon leads to the opposite effect lowering
the effectiveness of the compound and potentially leading to failure in the clinic [8, 9, 32].
Therefore, understanding mechanisms that lead to this undesired effect is important for
designing inhibitors that would avoid them. Indeed, a recent study proposed a novel inhibitor,
designed specifically to avoid MAPK activation at low-doses [79].
Our study could help achieve a similar goal. In particular, a straight forward approach to
mitigate the risk of hormetic response is to favour inhibitor mechanisms of action for which
this is impossible under our model. Protein substrate competitive inhibitors is one such exam-
ple as these would generally, through steric hindrance, prohibit the formation of the necessary
tertiary complex. In practice, structural biology can be employed to confirm that substrate and
inhibitor complexes are mutually exclusive.
Overall, we argue that mathematical models are particularly useful tools in the drug-discov-
ery process. Given the difficulties associated with measuring hormetic responses empirically
be it with reductionist in vitro biochemical assays or cell based systems, the involvement of
mathematical models in this process is of paramount importance. What we demonstrate here
is that theoretical models classically make assumptions that immediately discount the
Fig 5. Heterogeneous populations. Dose response curves of type-1 (green line) and type-2 (blue line) cells
in the presence of an inhibitor (inhtot), in the case when motif Eq (1) is bistable. A logistic curve (red line) is
fitted to sample points (red dots) generated numerically from a population containing 88% type-1 cells and
12% type-2 cells. The logistic fit to data is used to estimate IC50 of the total population (see Supplementary
Information). In the absence of the inhibitor type-1 cells are at CPP,1* stead state while type-2 cells are at
CPP,2*. In the presence of the inhibitor at IC50, while the total population exhibits 50% inhibition, the same
concentration has the opposing effects on the two sub-populations. In particular, type-1 cells are inhibited,
which can be deduced from the observation that the steady state CPP,1** calculated at the population-level
IC50 is lower than the steady state CPP,1* calculated in the absence of the inhibitor. Contrary to this type-2
cells are stimulated since the steady state CPP,2** calculated at the population-level IC50 is higher than the
steady state CPP,2* calculated in the absence of the inhibitor. This stimulatory effect is amplified even further
for IC*IC50, as seen by comparing the relatively high values of the steady state CPP,2[ at IC* to the relatively
low values of the steady state CPP,2* in the absence of the inhibitor.
doi:10.1371/journal.pcbi.1005216.g005
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possibility of observing hormetic responses in cell signalling pathways in the presence of inhib-
itors. Namely the assumption of no flux through substrate-kinase-inhibitor complex in motif
Eq (2) is widespread in theoretical literature despite the lack of empirical support. It is, there-
fore, crucial that model assumptions are regularly challenged so that important behaviours are
not overlooked.
Supporting Information
S1 Appendix. The file contains a detailed mathematical model describing the time evolu-
tion of the substrate, kinase, phosphate and inhibitor concentrations, alongside the corre-
sponding analysis and model parametrisation.
(PDF)
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